1-Alkyl-2-acetylglycerophosphocholine Esterase
"1-Alkyl-2-acetylglycerophosphocholine Esterase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lipoprotein-associated PHOSPHOLIPASE A2 which modulates the action of PLATELET ACTIVATING FACTOR by hydrolyzing the SN-2 ester bond to yield the biologically inactive lyso-platelet-activating factor. It has specificity for phospholipid substrates with short-chain residues at the SN-2 position, but inactive against long-chain phospholipids. Deficiency in this enzyme is associated with many diseases including ASTHMA, and HYPERCHOLESTEROLEMIA.
MeSH Number(s)
D08.811.277.352.100.680.750.937.249
Concept/Terms
1-Alkyl-2-acetylglycerophosphocholine Esterase- 1-Alkyl-2-acetylglycerophosphocholine Esterase
- 1 Alkyl 2 acetylglycerophosphocholine Esterase
- Esterase, 1-Alkyl-2-acetylglycerophosphocholine
- PAF 2-Acetylhydrolase
- 2-Acetylhydrolase, PAF
- PAF 2 Acetylhydrolase
- PAF 2-Acylhydrolase
- PAF 2 Acylhydrolase
- Lp-PLA(2)
- PAF Acetylhydrolase II
- Acetylhydrolase II, PAF
- Platelet-Activating Factor Hydrolase
- Factor Hydrolase, Platelet-Activating
- Hydrolase, Platelet-Activating Factor
- Platelet Activating Factor Hydrolase
- Lipoprotein-Associated Phospholipase A(2)
- Lipoprotein-Associated Phospholipase A2
- Lipoprotein Associated Phospholipase A2
- Phospholipase A2, Lipoprotein-Associated
- Lp-PLA2
- Lp PLA2
- PAF Acetylhydrolase
- Acetylhydrolase, PAF
Below are MeSH descriptors whose meaning is more general than "1-Alkyl-2-acetylglycerophosphocholine Esterase".
Below are MeSH descriptors whose meaning is more specific than "1-Alkyl-2-acetylglycerophosphocholine Esterase".
This graph shows the total number of publications written about "1-Alkyl-2-acetylglycerophosphocholine Esterase" by people in Harvard Catalyst Profiles by year, and whether "1-Alkyl-2-acetylglycerophosphocholine Esterase" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 3 | 4 |
| 2006 | 2 | 5 | 7 |
| 2007 | 3 | 0 | 3 |
| 2008 | 4 | 0 | 4 |
| 2009 | 1 | 0 | 1 |
| 2010 | 6 | 2 | 8 |
| 2011 | 2 | 1 | 3 |
| 2012 | 7 | 0 | 7 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 1 | 2 |
Below are the most recent publications written about "1-Alkyl-2-acetylglycerophosphocholine Esterase" by people in Profiles.
-
Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United States. Clin Infect Dis. 2023 01 13; 76(2):323-334.
-
PLA2G7/PAF-AH as Potential Negative Regulator of the Wnt Signaling Pathway Mediates Protective Effects in BRCA1 Mutant Breast Cancer. Int J Mol Sci. 2023 Jan 03; 24(1).
-
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1ß, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation. 2022 Aug 02; 146(5):372-379.
-
Role of renin-angiotensin-aldosterone system activation and other metabolic variables in relation to arterial inflammation in HIV. Clin Endocrinol (Oxf). 2022 11; 97(5):581-587.
-
Effects of Extended-Release Niacin on Quartile Lp-PLA2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial. J Cardiovasc Pharmacol Ther. 2019 11; 24(6):534-541.
-
Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease. PLoS One. 2018; 13(10):e0204352.
-
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. PLoS One. 2017; 12(7):e0182115.
-
Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity. Nature. 2017 04 12; 544(7649):235-239.
-
Sex Differences in Inflammatory Markers and Health Status Among Young Adults With Acute Myocardial Infarction: Results From the VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young Acute Myocardial Infarction Patients) Study. Circ Cardiovasc Qual Outcomes. 2017 02; 10(2):e003470.
-
Genetic invalidation of Lp-PLA2 as a therapeutic target: Large-scale study of five functional Lp-PLA2-lowering alleles. Eur J Prev Cardiol. 2017 03; 24(5):492-504.